Plant Comparison

Pygeum vs Saw Palmetto

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant APygeumPrunus africanaRosaceaeFull monograph →
Plant BSaw PalmettoSerenoa repensArecaceaeFull monograph →

At a glance

Pygeum and Saw Palmetto: they share 3 indicated uses (prostate support, urinary support, urinary tract infection (uti)).

PygeumSaw Palmetto
Constituents22
Pharmacological actions10
Indicated uses63
Safety notes22
Cited sources1314
Indicated uses
Only Pygeum
Arthritis / joint painInflammation (general)Skin irritation
Shared (3)
Prostate supportUrinary supportUrinary tract infection (UTI)
Only Saw Palmetto
none
Pharmacological actions
Only Pygeum
Anti-inflammatory
Shared (0)
none
Only Saw Palmetto
none

Evidence face-off — shared uses

ConditionPygeumSaw PalmettoVerdict
Prostate support10/1010/10Comparable evidence
Urinary support10/1010/10Comparable evidence
Urinary tract infection (UTI)9/108/10Comparable evidence

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Phytosterols (beta-sitosterol)[1, 10, 11, 12]

Sterols associated with the prostate-supporting activity.

Phytosterols
Pentacyclic triterpenes (ursolic and oleanolic acid) and ferulic acid esters[11]

Anti-inflammatory supporting constituents of the bark.

Ferulic acidTerpenes / terpenoids
Fatty acids and phytosterols (beta-sitosterol)[12]

The lipid/sterol fraction proposed to act on the prostate.

Phytosterols
Flavonoids[12]

Antioxidant constituents of the berry.

Flavonoids

Pharmacological Actions

Anti-inflammatory[6, 8, 10, 11]

Anti-inflammatory (prostate)

Not documented

Traditional & Indicated Uses

Arthritis / joint pain[11]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Arthritis / joint pain
Inflammation (general)[8]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Inflammation (general)
Prostate support[2, 3, 4, 5, 7, 11, 12, 13]Strong · 10/10

Supports lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - a Cochrane meta-analysis of 18 RCTs (1562 men) found a moderate improvement in urinary symptoms and flow versus placebo, but the trials were small, short and methodologically weak, so the evidence remains uncertain

Evidence: 10
Label: Prostate support
Skin irritation[11]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Skin irritation
Urinary support[2, 4, 5, 11, 12, 13]Strong · 10/10

Supports lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - a Cochrane meta-analysis of 18 RCTs (1562 men) found a moderate improvement in urinary symptoms and flow versus placebo, but the trials were small, short and methodologically weak, so the evidence remains uncertain

Evidence: 10
Label: Urinary support
Urinary tract infection (UTI)[11, 12, 13]Strong · 9/10

Supports lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - a Cochrane meta-analysis of 18 RCTs (1562 men) found a moderate improvement in urinary symptoms and flow versus placebo, but the trials were small, short and methodologically weak, so the evidence remains uncertain

Evidence: 9
Label: Urinary tract infection (UTI)
Prostate support[1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Strong · 10/10

Lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - widely used, but high-quality Cochrane evidence shows it is NOT better than placebo, even at double and triple doses

Evidence: 10
Label: Prostate support
Urinary support[1, 2, 3, 4, 5, 6, 10, 11, 12, 13]Strong · 10/10

General urinary support (traditional); Lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - widely used, but high-quality Cochrane evidence shows it is NOT better than placebo, even at double and triple doses

Evidence: 10
Label: Urinary support
Urinary tract infection (UTI)[12, 13]Good · 8/10

Lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - widely used, but high-quality Cochrane evidence shows it is NOT better than placebo, even at double and triple doses

Evidence: 8
Label: Urinary tract infection (UTI)

Safety, Cautions & Contraindications

Safety note[11, 13]Caution

Lower urinary tract / prostate symptoms must be medically assessed first to exclude prostate cancer. The evidence is mixed and rests on small, short, methodologically weak trials, so men with moderate or severe BPH should not rely on it instead of proven treatment.

Safety note[11]Info

Generally well tolerated, with mild gastrointestinal effects the most common report.

Safety note[12, 13]Caution

Generally well tolerated; mild gastrointestinal upset is the most common effect. BPH must be medically diagnosed (to exclude prostate cancer), and because the best evidence does not show benefit, saw palmetto should not replace proven treatment.

Safety note[12]Caution

Has mild anti-androgen and antiplatelet effects, so use caution with anticoagulant medicines and before surgery; avoid in pregnancy (hormonal activity).

External Ids

Gbif: 3022853
Wikidata: Q959738
Gbif: 2735055
Wikidata: Q927607

Botanical Description

Evergreen tree (Rosaceae), 10-30 m tall, with dark, fissured, red-brown bark (the source of the common name 'red stinkwood', from its unpleasant smell when cut). Leaves are glossy dark green, leathery, oblong with finely toothed margins. Small white, five-petalled flowers are borne in axillary racemes, followed by small reddish-brown, two-lobed fruit.

Height: 10-30 m
Habit: Evergreen tree
Leaves: Glossy dark green, leathery, oblong, finely toothed
Flowers: Small, white, five-petalled, in axillary racemes
Stem: Dark, fissured, red-brown, aromatic bark
Root: Deep woody root system
Fruit: Small, reddish-brown, two-lobed fruit
Flowering Period: Variable, often twice yearly in its native range

Low, clump-forming fan-palm shrub (Arecaceae), usually with a creeping or short, often prostrate trunk. Leaves are fan-shaped (palmate) on long, spiny-edged stalks. Small, creamy-white flowers are borne in branched clusters among the leaves, followed by large, dark blue-black, olive-sized berries - the part used.[12]

Height: Low, spreading; trunk often prostrate or short
Habit: Low, clump-forming fan-palm shrub
Leaves: Fan-shaped (palmate), on long, spiny-edged stalks
Flowers: Small, creamy-white, in branched clusters among the leaves
Stem: Creeping or short, often prostrate trunk
Root: Fibrous root system
Fruit: Large, dark blue-black, olive-sized berries
Flowering Period: Spring (April-June); berries ripen late summer to autumn

Habitat

Native to montane forests of central and southern Africa (and Madagascar), growing at moderate to high altitude (roughly 900-3400 m). The species is CITES-listed and conservation-threatened owing to over-harvesting of bark for the pharmaceutical trade.

Native to the south-eastern United States (particularly Florida and the Gulf Coast), a dominant understorey palm of coastal pine flatwoods, scrub and sandy coastal habitats.[12]

Harvesting

Bark is traditionally stripped from mature trees. Unsustainable stripping - especially removing bark all the way round the trunk - kills the tree and has driven population decline, so sustainable, partial and rotational bark harvesting or cultivated sources are recommended.

Parts: Bark
Season: Not standardised; sustainable/rotational harvesting recommended

Ripe berries are hand-harvested in late summer/autumn once they turn dark blue-black, then dried. Wild harvest is regulated in parts of the plant's native range given conservation concerns about overharvesting.[12]

Parts: Fruit (berry)
Season: Late summer to autumn

Traditional Uses

Prunus africana bark has a traditional use in East and Central African ethnomedicine for urinary complaints, and its extract (marketed as Pygeum) became one of the most widely used European phytotherapy remedies for benign prostatic hyperplasia (BPH) symptoms in the 20th century. Clinical evidence for symptom benefit is moderate but drawn from small, methodologically weak trials.[11]

Saw palmetto berries have a long Native American food and medicinal tradition, and were adopted into 19th- and 20th-century American and European phytotherapy as a tonic for the urinary and reproductive systems. The modern, most-studied use is for lower urinary tract symptoms of benign prostatic hyperplasia (BPH), though high-quality Cochrane evidence for pooled mixed extracts shows no benefit over placebo, while some meta-analyses of a specific standardised hexanic extract report symptom benefit.[12, 13]

Preparations

Standardised lipophilic bark extract (capsule)[11]

The clinically studied commercial form, standardised for phytosterol content.

Standardised lipophilic (hexanic) extract (capsule)[1, 2]

The most-studied commercial form (e.g. Permixon).

Dosage

Standardised extract[11]

Clinical trials have most often used around 100-200 mg/day of standardised lipophilic bark extract, divided into two doses. Educational reference only, not a prescription; any prostate or urinary symptom should be medically assessed first.

Standardised extract[12, 13]

Clinical trials have most often used around 160 mg of standardised extract twice daily (320 mg/day total). Educational reference only, not a prescription; any prostate or urinary symptom should be medically assessed first, and saw palmetto should not replace proven treatment given uncertain efficacy evidence.

References

REF-1506, REF-1507, REF-1508, REF-1509, REF-1510, REF-1511, REF-1512, REF-1513, REF-1514, REF-1515
REF-0571, REF-0572, REF-1887, REF-1888, REF-1889, REF-1890, REF-1891, REF-1892, REF-1893, REF-1894, REF-1895

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

Drug Class Interactions

Not documented

Safety note[14]Caution
Drug Class: anticoagulants-antiplatelets
Mechanism: Saw palmetto has been linked to prolonged bleeding time, and a case of severe intraoperative haemorrhage was reported in a patient taking it; combining it with anticoagulant or antiplatelet drugs may add to bleeding risk, so stop it before surgery.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

References & Sources

  1. Thompson, R.Q., Katz, D. and Sheehan, B (2019) 'Chemical comparison of Prunus africana bark and pygeum products marketed for prostate health', Journal of Pharmaceutical and Biomedical Analysis, 163, pp. 162-169. doi:10.1016/j.jpba.2018.10.004 Preclinical
    https://doi.org/10.1016/j.jpba.2018.10.004
  2. Dvorkin, L. and Song, K.Y (2002) 'Herbs for benign prostatic hyperplasia', The Annals of Pharmacotherapy, 36(9), pp. 1443-1452. doi:10.1345/aph.1A228 Meta-analysis / review
    https://doi.org/10.1345/aph.1A228
  3. Keehn, A. and Lowe, F.C (2015) 'Complementary and alternative medications for benign prostatic hyperplasia', The Canadian Journal of Urology, 22(Suppl 1), pp. 18-23. Meta-analysis / review
    https://scholar.google.com/scholar?q=Complementary%20and%20alternative%20medications%20for%20benign%20prostatic%20hyperplasia
  4. Kim, T.H., Lim, H.J., Kim, M.S. and Lee, M.S (2012) 'Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews', Maturitas, 73(3), pp. 180-185. doi:10.1016/j.maturitas.2012.07.007 Meta-analysis / review
    https://doi.org/10.1016/j.maturitas.2012.07.007
  5. Cambronero, J., Osca-Garcia, J.M., Merino-Salas, S., Miguel, J.M. and others (2022) 'Effectiveness of treatment with Pygeum africanum in patients with lower urinary tract symptoms and benign prostatic hyperplasia: a cross-sectional study in the real-world clinical practice in Spain (The PROFIT Study)', Archivos Espanoles de Urologia, 75(3), pp. 219-227. Clinical study
    https://scholar.google.com/scholar?q=Effectiveness%20of%20treatment%20with%20Pygeum%20africanum%20in%20patients%20with%20lower%20urinary%20tract%20symptoms%20and%20benign%20prostatic%20hyperplasia%3A%20a%20cross-sectional%20study%20in%20the%20real-world%20clinical%20practice%20in%20Spain%20%28The%20PROFIT%20Study%29
  6. Quiles, M.T., Arbos, M.A., Fraga, A., de Torres, I.M. and others (2010) 'Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)', The Prostate, 70(10), pp. 1044-1053. doi:10.1002/pros.21138 Preclinical
    https://doi.org/10.1002/pros.21138
  7. Salinas-Casado, J., Esteban-Fuertes, M., Carballido-Rodriguez, J. and Cozar-Olmo, J.M (2020) 'Review of the experience and evidence of Pygeum africanum in urological practice', Actas Urologicas Espanolas, 44(1), pp. 9-13. doi:10.1016/j.acuro.2019.08.002 Meta-analysis / review
    https://doi.org/10.1016/j.acuro.2019.08.002
  8. Villar, A., Silva-Fuentes, F., Mula, A. and Zangara, A (2024) 'Anti-Inflammatory Potential of Prunus africana Bark Extract: An In Vitro Study of Cytokine Release by Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells', International Journal of Molecular Sciences, 25(15), pp. 8298. doi:10.3390/ijms25158298 Preclinical
    https://doi.org/10.3390/ijms25158298
  9. Larre, S., Camparo, P., Comperat, E., Boulbes, D. and others (2012) 'Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures', Asian Journal of Andrology, 14(3), pp. 499-504. doi:10.1038/aja.2011.132 Preclinical
    https://doi.org/10.1038/aja.2011.132
  10. Rubegeta, E., Makolo, F., Kamatou, G., Enslin, G. and others (2023) 'The African cherry: A review of the botany, traditional uses, phytochemistry, and biological activities of Prunus africana (Hook.f.) Kalkman', Journal of Ethnopharmacology, 305, pp. 116004. doi:10.1016/j.jep.2022.116004 Meta-analysis / review
    https://doi.org/10.1016/j.jep.2022.116004
  11. Keehn, A. and Lowe, F.C (2015) 'Complementary and alternative medications for benign prostatic hyperplasia', The Canadian Journal of Urology. Randomized trial
    https://scholar.google.com/scholar?q=Complementary%20and%20alternative%20medications%20for%20benign%20prostatic%20hyperplasia
  12. Dedhia, R.C. and McVary, K.T (2008) 'Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia', The Journal of Urology, 179(6), pp. 2119--2125. doi:10.1016/j.juro.2008.01.094 Meta-analysis / review
    https://doi.org/10.1016/j.juro.2008.01.094
  13. Wilt, T. and Ishani, A. and Mac Donald, R. and Rutks, I. and Stark, G (2002) 'Pygeum africanum for benign prostatic hyperplasia', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001044 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD001044
  1. Vela-Navarrete, R., Alcaraz, A., Rodriguez-Antolin, A., Minana Lopez, B., Fernandez-Gomez, J.M. and others (2018) 'Efficacy and safety of a hexanic extract of Serenoa repens (Permixon) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies', BJU International, 122(6), pp. 1049--1065. doi:10.1111/bju.14362 Meta-analysis / review
    https://doi.org/10.1111/bju.14362
  2. Novara, G., Giannarini, G., Alcaraz, A., Cozar-Olmo, J.M., Descazeaud, A., Montorsi, F. and Ficarra, V (2016) 'Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials', European Urology Focus, 2(5), pp. 553--561. doi:10.1016/j.euf.2016.04.002 Meta-analysis / review
    https://doi.org/10.1016/j.euf.2016.04.002
  3. Franco, J.V., Trivisonno, L., Sgarbossa, N.J., Alvez, G.A., Fieiras, C., Escobar Liquitay, C.M. and Jung, J.H (2023) 'Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement', Cochrane Database of Systematic Reviews, 6(6), pp. CD001423. doi:10.1002/14651858.CD001423.pub4 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD001423.pub4
  4. Ooi, S.L. and Pak, S.C (2017) 'Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine', Journal of Alternative and Complementary Medicine, 23(8), pp. 599-606. doi:10.1089/acm.2016.0302 Meta-analysis / review
    https://doi.org/10.1089/acm.2016.0302
  5. Cai, T., Cui, Y., Yu, S., Li, Q., Zhou, Z. and Gao, Z (2020) 'Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis', American Journal of Men's Health, 14(2), pp. 1557988320905407. doi:10.1177/1557988320905407 Meta-analysis / review
    https://doi.org/10.1177/1557988320905407
  6. Trivisonno, L.F., Sgarbossa, N., Alvez, G.A., Fieiras, C., Escobar Liquitay, C.M., Jung, J.H. and Franco, J.V.A (2021) 'Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis', Investigative and Clinical Urology, 62(5), pp. 520-534. doi:10.4111/icu.20210254 Meta-analysis / review
    https://doi.org/10.4111/icu.20210254
  7. Kwon, Y (2019) 'Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia', Food Science and Biotechnology, 28(6), pp. 1599-1606. doi:10.1007/s10068-019-00605-9 Meta-analysis / review
    https://doi.org/10.1007/s10068-019-00605-9
  8. MacDonald, R., Tacklind, J.W., Rutks, I. and Wilt, T.J (2012) 'Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review', BJU International, 109(12), pp. 1756-1761. doi:10.1111/j.1464-410X.2012.11172.x Meta-analysis / review
    https://doi.org/10.1111/j.1464-410X.2012.11172.x
  9. Minutoli, L., Bitto, A., Squadrito, F., Marini, H., Irrera, N., Morgia, G., Passantino, A. and Altavilla, D (2013) 'Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia', Current Medicinal Chemistry, 20(10), pp. 1306-1312. doi:10.2174/0929867311320100007 Meta-analysis / review
    https://doi.org/10.2174/0929867311320100007
  10. Boyle, P., Robertson, C., Lowe, F. and Roehrborn, C (2004) 'Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia', BJU International, 93(6), pp. 751-756. doi:10.1111/j.1464-410X.2003.04735.x Meta-analysis / review
    https://doi.org/10.1111/j.1464-410X.2003.04735.x
  11. Willetts, K.E., Clements, M.S., Champion, S., Ehsman, S. and Eden, J.A (2003) 'Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial', BJU International, 92(3), pp. 267-270. doi:10.1046/j.1464-410x.2003.04316.x Randomized trial
    https://doi.org/10.1046/j.1464-410x.2003.04316.x
  12. Keehn, A. and Lowe, F.C (2015) 'Complementary and alternative medications for benign prostatic hyperplasia', The Canadian Journal of Urology. Randomized trial
    https://scholar.google.com/scholar?q=Complementary%20and%20alternative%20medications%20for%20benign%20prostatic%20hyperplasia
  13. Tacklind, J., Macdonald, R., Rutks, I., Stanke, J.U. and Wilt, T.J (2012) 'Serenoa repens for benign prostatic hyperplasia', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001423.pub3 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD001423.pub3
  14. Cheema, P., El-Mefty, O. and Jazieh, A.R (2001) 'Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature', Journal of Internal Medicine, 250(2), pp. 167-169. doi:10.1046/j.1365-2796.2001.00851.x Clinical study
    https://doi.org/10.1046/j.1365-2796.2001.00851.x

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.